暗記メーカー
暗記メーカー
ログイン
CLINICAL CHEMISTRY
  • Yves Laure Pimentel

  • 問題数 100 • 7/30/2024

    記憶度

    完璧

    15

    覚えた

    35

    うろ覚え

    0

    苦手

    0

    未解答

    0

    アカウント登録して、解答結果を保存しよう

    問題一覧

  • 1

    All of the following statements about iodine are true, EXCEPT: a. Radioactive iodine treatment of Graves’ disease is effective in less than 40% of patients treated with this agent. b. Iodine deficiency is one of the most common causes of hypothyroidism in the world. c. T4 has four iodine molecules. d. RAIU is often useful in determining the cause of thyrotoxicosis.

    a. Radioactive iodine treatment of Graves’ disease is effective in less than 40% of patients treated with this agent.

  • 2

    The fetus: a. Is dependent on thyroid hormone for normal neurologic development. b. Does not develop a thyroid gland until the third trimester. c. Is not susceptible to damage from radioactive iodine therapy given to the mother. d. Will be born with hypothyroidism in approximately 1 of 400 births in developed countries.

    a. Is dependent on thyroid hormone for normal neurologic development.

  • 3

    The thyroid gland: a. Depends on TPO to permit iodination of the tyrosyl residues to make MIT and DIT. b. Is an ineffective iodine trap c. Depends on TPO to permit the joining of two DIT residues to form T3 d. Usually functions independent of TSH levels.

    a. Depends on TPO to permit iodination of the tyrosyl residues to make MIT and DIT.

  • 4

    The thyroid gland produces: (1) TSH (2) Thyroglobulin (3) T3 (4) T4 a. 1, 2, and 3 b. 2, 3, and 4 c. 1, 3, and 4 d. 1, 2, and 4

    b. 2, 3, and 4

  • 5

    Hypothyroidism is generally associated with all of the following, EXCEPT: a. TSH receptor antibodies b. Depression c. An elevation of TSH levels d. TPO antibodies

    a. TSH receptor antibodies

  • 6

    A 34-year-old women presents with goiter, tachycardia, and weight loss of 2 months duration. TSH is undetectable and free T4 is high. All of the following tests are useful in diagnosing the cause of the hyperthyroidism, EXCEPT: a. FNA biopsy of the thyroid gland b. TSH receptor antibodies c. RAIU d. TSH

    a. FNA biopsy of the thyroid gland

  • 7

    A 65-year-old woman presents with fatigue, hypothermia, pericardial effusions, and hair loss. Her thyroid function tests show significantly elevated TSH and a low free T4. All of the following laboratory test abnormalities may be associated with her underlying condition, EXCEPT: a. Elevated WBC b. An elevated cholesterol level c. Anemia d. Elevated CPK level

    a. Elevated WBC

  • 8

    A 26-year-old man presents with a 3-cm, right lobe, thyroid nodule and a normal TSH. What is the next test that should be performed? a. FNA of the nodule b. Free T4 level c. Thyroid ultrasound d. Thyroid scan

    a. FNA of the nodule

  • 9

    The following are treatment options for hyperthyroidism associated with Graves’ disease, EXCEPT: a. Thyroid hormone b. PTU c. Beta-blockers d. Radioactive iodine

    a. Thyroid hormone

  • 10

    All of the following abnormalities might be expected in a severely ill patient, EXCEPT: a. Low rT3 b. Low T4 c. Low T3 d. Low TSH

    a. Low rT3

  • 11

    Of the following thyroid hormones, which is considered the most biologically active? a. T3 bound to TBG b. T4 bound to TBG c. Free T4 d. Free T3 e. rT3

    d. Free T3

  • 12

    he primary serum test to screen for thyroid disease is: a. Free T4 b. rT3 c. Total T4 d. Autoimmune antibodies to thyroid tissue e. TSH

    e. TSH

  • 13

    Of the following, which will MOST likely interfere with quantitation of thyroglobulin? a. Antithyroglobulin antibodies b. Thyroid-stimulating antibodies c. TSH receptor antibodies d. Thyroid peroxidase antibodies

    a. Antithyroglobulin antibodies

  • 14

    Parathyroid hormones and 1,25-(OH)2D (vitamin D) are the principal hormones involved in the normal physiologic regulation of calcium homeostasis: a. True b. False c. Too little data d. None of these

    a. True

  • 15

    Primary organs involved in the maintenance of calcium homeostasis: (1) Intestine (GI tract) (2) Bone (3) Kidney a. 1 and 2 b. 2 and 3 c. 1 and 3 d. 1, 2, and 3

    d. 1, 2, and 3

  • 16

    Organs involved in the production of the active metabolite of vitamin D: (1) Skin (2) Liver (3) Kidneys a. 1 and 2 b. 2 and 3 c. 1 and 3 d. 1, 2, and 3

    d. 1, 2, and 3

  • 17

    Cod liver oil is a source of vitamin D: a. True b. False c. Too little data d. Cod liver oil is not edible

    a. True

  • 18

    1,25(OH)2D is the best blood test for determining adequacy of vitamin D stores in the body. a. True b. False c. Too little data d. None of these

    b. False

  • 19

    PTHrP is produced by some cancers and often leads to cancer-associated hypercalcemia. a. True b. False c. Too little data d. None of these

    a. True

  • 20

    1,25(OH)2D, due to 1-hydroxylase activity in macrophages, may be produced to excess in granulomatous diseases and lymphoid disorders, leading to hypercalcemia. a. True b. False c. Too little data d. None of these

    a. True

  • 21

    In PHPT, the defect primarily lies in ____. In secondary hyperparathyroidism, the defect primarily lies with the threat of _____ to the body. a. Parathyroid gland, hypercalcemia b. Parathyroid gland, hypocalcemia c. Thyroid gland, hypercalcemia d. Thyroid gland, hypocalcemia

    b. Parathyroid gland, hypocalcemia

  • 22

    Development of ________ is the primary complication of hypercalciuria. a. Gout arthritis b. Pseudogout c. Kidney stones d. None of these

    c. Kidney stones

  • 23

    What is the most common cause of hypoparathyroidism? a. Magnesium deficiency b. Hashimoto’s thyroiditis c. Grave’s disease d. Neck surgery

    d. Neck surgery

  • 24

    What is the type of bone most rapidly lost in response to hypogonadism and glucocorticoid therapy? a. Cortical bone b. Trabecular bone c. Sphenoid bone d. None of these

    b. Trabecular bone

  • 25

    ________ cells in the bone are responsible for bone resorption, and the _______ cells are responsible for bone formation. a. Osteoclasts, osteoblasts b. Osteoblasts, osteoclasts c. Osteoblasts, osteoblasts d. Osteoclasts, osteoclasts

    a. Osteoclasts, osteoblasts

  • 26

    Which of the following is the most prevalent metabolic bone disease in adults? a. Osteomalacia b. Osteosarcoma c. Paget’s disease d. Osteoporosis

    d. Osteoporosis

  • 27

    Hormone replacement does not inhibit bone resorption in osteoporotic patients. a. True b. False c. Too little data d. None of these

    b. False

  • 28

    Which of the following enzymes would best aid in identifying hepatobiliary disease? a. ALP b. AST c. ALT d. Ammonia

    a. ALP

  • 29

    Teriparatide is the only drug currently approved by the FDA for the treatment of osteoporosis that directly stimulates bone formation. a. True b. False c. Too little data d. None of these

    a. True

  • 30

    In which of the following types of cells does the conjugation of bilirubin take place? a. Hepatocytes b. Kupffer cells c. Macrophages d. Phagocytic cells

    a. Hepatocytes

  • 31

    Which of the following enzymes is responsible for the conjugation of bilirubin? a. UDP-glucuronosyltransferase b. Alkaline phosphatase c. Glutamate dehydrogenase d. Leucine aminopeptidase

    a. UDP-glucuronosyltransferase

  • 32

    Which of the following fractions of bilirubin is water soluble and reacts with a diazo reagent without the addition of an accelerator? a. Conjugated bilirubin b. Unconjugated bilirubin c. Total bilirubin d. Indirect bilirubin

    a. Conjugated bilirubin

  • 33

    Which form of hepatitis is caused by a DNA virus? a. Hepatitis B b. Hepatitis A c. Hepatitis C d. Hepatitis D

    a. Hepatitis B

  • 34

    Which of the following enzymes is most useful in establishing the hepatic origin of an elevated serum alkaline phosphatase? a. 5’-Nucleotidase b. Alanine aminotransferase (ALT) c. Aspartate aminotransferase (AST) d. Lactate dehydrogenase

    a. 5’-Nucleotidase

  • 35

    Hepatitis E is likely to cause serious consequences in: a. Pregnant women b. Children c. Travelers in Third World countries d. Older people

    a. Pregnant women

  • 36

    Worldwide, most primary malignant tumors of the liver are related to: a. Alcoholism b. Gallstones c. Reye’s syndrome d. Malaria

    a. Alcoholism

  • 37

    The reagent p-dimethylaminobenzaldehyde is used to measure which of the following? a. Urobilinogen b. Total bilirubin c. Ammonia d. Alkaline phosphatase

    a. Urobilinogen

  • 38

    Which of the following conditions would result in elevations in primarily conjugated bilirubin? a. Dubin-Johnson syndrome b. Physiologic jaundice of the newborn c. Crigler-Najjar syndrome d. Gilbert’s syndrome

    a. Dubin-Johnson syndrome

  • 39

    A urinalysis dipstick test indicated that urobilinogen was absent. Which condition does this support? a. Biliary obstruction b. Hepatitis A acute infection c. Defective liver cell function d. Hepatocellular disease e. This would support all of the above condition

    a. Biliary obstruction

  • 40

    Measuring serum ammonia levels has the potential to be fraught with preanalytical errors that may interfere with achieving an accurate result. Of the following preanalytical steps, which is incorrect? a. After phlebotomy, the patient’s blood should be immediately placed on ice. b. The blood should be collected in a red clot tube without anticoagulant c. Hemolyzed samples should be rejected as this interferes by falsely increasing ammonia measurements d. Lipemia may also interfere with plasma ammonia measurements e. All of the above are correct.

    b. The blood should be collected in a red clot tube without anticoagulant

  • 41

    A patient presents with elevated levels of IgG anti-HAV, while levels of IgM anti-HAV are nondetectable. This patient is likely to: a. Have an acute infection of HAV b. Have a chronic infection of HAV c. Have an immunity to HAV d. Be a carrier of HAV

    c. Have an immunity to HAV

  • 42

    The product produced and measured when reacting bilirubin with a diazo reagent is: a. NADPH b. NAD c. Azobilirubin d. Bilirubin diglucuronide

    c. Azobilirubin

  • 43

    A healthy 28-year-old female sees her physician for a routine examination and has received a “relatively” clean bill of health except for the results below. Total bilirubin 2.8 mg/dL Direct bilirubin 0.1 mg/dL Indirect bilirubin 2.7 mg/dL These results most likely indicate? a. Normal bilirubin metabolism b. Extrahepatic obstruction c. Dubin-Johnson syndrome d. Gilbert’s syndrome

    d. Gilbert’s syndrome

  • 44

    Which of the following is measured using glutamate dehydrogenase and is a measure of advanced stages, poor prognosis, and coma in liver disease? a. Total bilirubin b. Ammonia c. Unconjugated bilirubin d. Urea

    b. Ammonia

  • 45

    In which of the following disease states would you see an elevation in total bilirubin and conjugated bilirubin only? a. Biliary obstruction b. Hemolysis c. Neonatal jaundice d. Gilbert’s disease

    a. Biliary obstruction

  • 46

    As a reduction product of bilirubin catabolism, this compound is partially reabsorbed from the intestines through the portal circulation for reexcretion by the liver. What is this compound? a. Urobilinogen b. Azobilirubin c. Biliverdin d. Urobilin d. Bilirubin

    a. Urobilinogen

  • 47

    You are the technologist on duty and you are performing the following assay: Patient sample + Diazo reagent + Accelerator → Product Which fraction(s) of bilirubin will react in the above reaction? a. Conjugated b. Delta c. Unconjugated d. All of the above

    d. All of the above

  • 48

    Choose the diagnosis most consistent with the following laboratory findings: Total bilirubin 5.8 mg/dL Direct bilirubin 0.1 mg/dL Indirect bilirubin 5.7 mg/dL a. Physiologic jaundice of the newborn b. Posthepatic bile obstruction c. Dubin-Johnson syndrome d. Rotor’s syndrome e. None of the above

    a. Physiologic jaundice of the newborn

  • 49

    A serum TnT concentration is of most value to the patient with an MI when: a. The CK-MB has already peaked and returned to normal concentrations b. The onset of symptoms is within 3 to 6 hours of the sample being drawn c. The myoglobin is extremely elevated d. The TnI concentration has returned to normal concentrations.

    a. The CK-MB has already peaked and returned to normal concentrations

  • 50

    A normal myoglobin concentrations 8 hours after the onset of symptoms of a suspected MI will: a. Essentially rule out an acute MI b. Provide a definitive diagnosis of acute MI c. Be interpreted with careful consideration of the TnT concentration d. Give the same information as a total CK-MB

    c. Be interpreted with careful consideration of the TnT concentration

  • 51

    Which of the following analytes has the highest specificity for cardiac injury? a. TnI b. CK-MB mass assays c. Total CK-MB d. AST

    a. TnI

  • 52

    Which of the following newer markers of inflammation circulates in serum bound to LDL and HDL? a. Lipoprotein-associated phospholipase A2 b. CK-MB c. cTnI d. hsCRP

    a. Lipoprotein-associated phospholipase A2

  • 53

    A person with a confirmed blood pressure of 125/87 would be classified as: a. Prehypertension b. Normal c. Stage 1 hypertension d. Stage 2 hypertension

    a. Prehypertension

  • 54

    Rheumatic heart disease is a result of infection with which of the following organisms? a. Group A streptococci b. Staphylococcus aureus c. Pseudomonas aeruginosa d. Chlamydia pneumoniae

    a. Group A streptococci

  • 55

    Which of the following defects is the most common type of congenital CVD encountered? a. Ventricular septal defects (VSD) b. Tetralogy of Fallot c. Coarctation of the aorta d. Transposition of the great arteries

    a. Ventricular septal defects (VSD)

  • 56

    Which of the following cardiac markers is the most useful indicator of congestive heart failure? a. BNP b. TnI c. CK-MB d. Glycogen phosphorylase isoenzyme B

    a. BNP

  • 57

    Which of the following is the preferred biomarker for the assessment of myocardial necrosis? a. CK b. AST c. CK-MB d. Cardiac troponin (I or T)

    d. Cardiac troponin (I or T)

  • 58

    Which of the following is not a feature of an ideal cardiac marker? a. Ability to predict future occurrence of cardiac disease b. Absolute specificity c. High sensitivity d. Close estimation of the magnitude of cardiac damage.

    a. Ability to predict future occurrence of cardiac disease

  • 59

    Renin release by the kidney is stimulated by: a. A decrease in extracellular fluid volume or pressure b. Increased plasma sodium concentration c. Increased dietary sodium d. Renal tubular reabsorption

    a. A decrease in extracellular fluid volume or pressure

  • 60

    The measurement of serum Cystatin C, a small protein produced by nucleated cells, is useful for: a. Detecting an early decrease in kidney function b. Calculating creatinine clearance c. Diagnosing end-stage renal disease d. Monitoring dialysis patients

    a. Detecting an early decrease in kidney function

  • 61

    The proximal tubule functions to: a. Reabsorb 75% of salt and water b. Concentrate salts c. Form the renal threshold d. Reabsorb urea

    a. Reabsorb 75% of salt and water

  • 62

    Renal clearance: a. Volume of plasma from which a substance is removed per unit of time b. Volume of urine produced per day c. Amount of creatinine in urine d. Urine concentration of a substance divided by the urine volume per unit of time

    a. Volume of plasma from which a substance is removed per unit of time

  • 63

    Creatinine clearance results are corrected using a patient’s body surface area to account for differences in: a. Muscle mass b. Age c. Dietary intake d. Sex

    a. Muscle mass

  • 64

    A patient is suffering from an acute bleed. What is the most accurate way to describe the subsequent acute kidney injury? a. Prerenal acute kidney injury b. Renal acute kidney injury c. Postrenal acute kidney injury d. None of the above apply

    a. Prerenal acute kidney injury

  • 65

    Which of the following tests is only of the absorptive ability of the intestine? a. D-Xylose test b. Lactose tolerance test c. Fecal fat (72-hour collection) d. Serum carotenoids e. Serum albumin

    a. D-Xylose test

  • 66

    The D-Xylose absorption test is particularly helpful in differentiation malabsorption of intestinal etiology from exocrine pancreatic insufficiency because: a. D-xylose is mostly absorbed in the stomach and then secreted via the kidney in its unaltered monosaccharide form. b. D-xylose is mostly altered in the small intestine to facilitate its absorption across this membrane and metabolized by the liver so its metabolites may be excreted via the kidney. c. D-xylose is mostly absorbed, not typically found in the blood, unaltered in the small intestine, and excreted unaltered via the kidney. d. None of these

    c. D-xylose is mostly absorbed, not typically found in the blood, unaltered in the small intestine, and excreted unaltered via the kidney.

  • 67

    266. Which of the following statements concerning cystic fibrosis is NOT correct? a. Affects males and females about equally b. Occurs predominantly in population of Northern European extraction c. Frequently diagnosed by measurement of sweat chloride. d. Caused by a variety of mutation on chromosome seven. e. Genetic screening is usually unsuccessful.

    e. Genetic screening is usually unsuccessful.

  • 68

    Laboratory findings in pancreatitis include all of the following, except: a. Increased cortisol b. Increased amylase c. Increased lipase d. Increased triglycerides

    a. Increased cortisol

  • 69

    Which of the following tests is direct determination of the exocrine secretory capacity of the pancreas? a. Secretin/CCK test b. Amylase c. Quantitative decal fat analysis d. D-Xylose test e. Lactose tolerance test

    a. Secretin/CCK test

  • 70

    A serum albumin of less than 2.5 g/dL would be most indicative of: a. Intestinal disease b. Pancreatitis c. Peptic ulcer d. Pancreatic carcinoma

    a. Intestinal diseas

  • 71

    Which of the following is accurate when describing or diagnosing Zollinger-Ellison syndrome? a. Extreme hyposecretion of gastrin in the stomach b. Extreme hypersecretion of gastrin in the duodenum c. An increase in serum gastrin levels of 100 pg/mL following IV exposure to secretin. d. A decrease in serum gastrin levels of 100 pg/mL following IV exposure to secretin

    c. An increase in serum gastrin levels of 100 pg/mL following IV exposure to secretin.

  • 72

    If a trough specimen is required for therapeutic drug monitoring, the most appropriate time to collect the specimen would be: a. Eight hours after the last dose was given. b. Three days after the dose was administered c. Immediately after the dose is administered d. Immediately before the next dose is given.

    d. Immediately before the next dose is given.

  • 73

    Of the following analytic methods, which is most commonly used as the confirmatory method for identification of drugs of abuse? a. GC with mass spectrometry b. Scanning differential calorimetry c. Ion-specific electrode d. Immunoassay e. Nephelometry

    a. GC with mass spectrometry

  • 74

    REFERENCE METHODS GLUCOSE-

    HEXOKINASE

  • 75

    REFERENCE METHODS CHOLESTEROL-

    GCMS

  • 76

    REFERENCE METHODS TRIGLYCERIDE-

    GCMS

  • 77

    REFERENCE METHODS GLOMERULAR FILTRATION RATE-

    INULIN CLEARANCE

  • 78

    REFERENCE METHODS NPNS

    IDM

  • 79

    Which of the following statement(s) is true? (1) Lithium is used to treat depression, selfmutilating behavior, and bipolar disorder. (2) Procainamide is metabolized into an active metabolite with similar anti-arrhythmic activity. (3) Methotrexate is measured in serum to determine amount of leucovorin needed. a. 1 and 2 b. 2 and 3 c. 1 and 3 d. 1, 2, and 3

    d. 1, 2, and 3

  • 80

    If a drug is administered orally, which of the following would affect the efficiency of its absorption in the GI tract? (1) Dissociation of the drug from its administered form. (2) The drug’s solubility in gastrointestinal fluid (3) Diffusion of the drug across GI membranes a. 1 and 2 b. 2 and 3 c. 1 and 3 d. 1, 2, and 3

    d. 1, 2, and 3

  • 81

    Primidone is an inactive preform of which of the following antiepileptic drugs? a. Gabapentin b. Clozapine c. Phenobarbital d. Ethosuximide

    c. Phenobarbital

  • 82

    Which of the following statements concerning cyanide toxicity is TRUE? a. Inhalation of smoke from burning plastic is a common cause of cyanide exposure, and cyanide expresses its toxicity by inhibition of oxidative phosphorylation b. Inhalation of smoke from burning plastic is a common cause of cyanide exposure c. Cyanide is relatively nontoxic compound that requires chronic exposure to produce a toxic effect d. Cyanide expresses its toxicity by inhibition of oxidative phosphorylation. e. All of these are true.

    a. Inhalation of smoke from burning plastic is a common cause of cyanide exposure, and cyanide expresses its toxicity by inhibition of oxidative phosphorylation

  • 83

    What is the primary product of methanol metabolism by the ADH and ALDH system? a. Formic acid b. Acetone c. Acetaldehyde d. Oxalic acid e. Formaldehyde

    a. Formic acid

  • 84

    Which of the following laboratory results would be consistent with acute high-level oral exposure to an inorganic form of mercury (Hg2+)? a. All of these b. High concentrations of mercury in whole blood and urine c. Proteinuria d. Positive occult blood in stool e. one of these

    a. All of these

  • 85

    A child presents with microcytic, hypochromic anemia. The physician suspects IDA. Further laboratory testing reveals a normal total serum iron and iron-binding capacity; however, the zinc protoporphyrin level was very high. A urinary screen for porphyrins was positive. Erythrocytic basophilic stippling was noted on the peripheral smear. Which of the following laboratory test would be best applied to this case? a. Whole blood lead b. Urinary thiocyanate c. COHb d. Urinary anabolic steroids e. Urinary benzoylecgonine

    a. Whole blood lead

  • 86

    A patient with suspected organophosphate poisoning presents with a low SChE level. However, the confirmatory test, erythrocyte acetylcholinesterase, presents with a normal result. Excluding analytic error, which of the following may explain these conflicting results? a. The patient has late-stage hepatic cirrhosis or the patient has a variant of SChE that displays low activity. b. The patient has late-stage hepatic cirrhosis. c. The patient was exposed to low levels of organophosphates. d. The patient has a variant of SChE that displays low activity. e. All of these are correct

    a. The patient has late-stage hepatic cirrhosis or the patient has a variant of SChE that displays low activity.

  • 87

    A patient enters the emergency department in a coma. The physician suspects a drug overdose. Immunoassay screening tests for opiates, barbiturates, benzodiazepines, THC, amphetamines, and PCP were all negative. No ethanol was detected in serum. Can the physician rule out drug overdose as the cause of this coma with these results? a. No b. Yes c. Maybe

    a. No

  • 88

    Compound A is reported to have an oral LD50 of 5 mg/kg body weight. Compound B is reported to have an LD50 of 50 mg/kg body weight. Of the following statements regarding the relative toxicity of these two compounds, which is TRUE? a. Ingestion of low amounts of compound A would be predicted to cause more deaths than an equal dose of compound B. b. Ingestion of compound B would be expected to produce nontoxic effects at a dose greater than 100 mg/kg body weight.

    a. Ingestion of low amounts of compound A would be predicted to cause more deaths than an equal dose of compound B.

  • 89

    Which of the following statements best describes the TD50 of a compound? a. The dosage of a substance that would be predicted to cause a toxic effect in 50% of the population b. The dosage of a substance that is lethal to 50% of the population c. The dosage of a substance that would produce therapeutic benefit in 50% of the population d. The percentage of individuals who would experience a toxic response at 50% of the lethal dose

    a. The dosage of a substance that would be predicted to cause a toxic effect in 50% of the population

  • 90

    A weakly acidic toxin (pKa = 4.0) that is ingested will a. Be passively absorbed in the stomach (pH = 3.0) b. Not be absorbed because it is ionized c. Not be absorbed unless a specific transporter is present d. Be passively absorbed in the colon (pH = 7.5)

    a. Be passively absorbed in the stomach (pH = 3.0)

  • 91

    Select the appropriate letter regarding tumor marker test: (1) Screen for cancer (2) Aid in staging cancer (3) Monitor response to therapy (4) Detect recurrent disease a. All of the above b. 1, 2, and 3 c. 2, 3, and 4 d. 1, 2, and 4 e. 4 only

    a. All of the above

  • 92

    Which of the following methods is commonly used to measure endocrine metabolites? a. Protein electrophoresis b. Immunoassays c. HPLC d. Electrochemistry e. Gas chromatography

    c. HPLC

  • 93

    Which of the following nutritional markers has been found to be the most sensitive and helpful indicator of nutritional status in very ill patients? a. Transthyretin b. Transferrin c. Albumin d. Somatomedin C

    a. Transthyretin

  • 94

    Which of the following describes the correct source, function, and deficient state of the vitamin listed? a. Thiamine (B1)-whole grains, carbohydrate metabolism, beriberi b. Vitamin E-plants tissues, antioxidant, Osteomalacia. c. Niacin- meat, oxidation-reduction reaction, scurvy d. Folic acid- dairy products, myelin formation

    a. Thiamine (B1)-whole grains, carbohydrate metabolism, beriberi

  • 95

    Hearing loss is common among the elderly and may cause embarrassment. What should be done to facilitate the specimen collection process? a. Adjust your position to speak into the ear with the best hearing b. Speak very loudly and forcefully. c. Don’t speak at all. Just give the patient printed instructions d. Use a microphone.

    a. Adjust your position to speak into the ear with the best hearing

  • 96

    Under normal conditions, what is the maximum amount of blood that should be drawn from a 30-kg child during a single blood draw? a. 60 mL b. 80 mL c. 40 mL d. 20 mL

    a. 60 mL

  • 97

    When choosing a chemistry analyzer for a pediatric laboratory, it is necessary to: a. Incorporate total laboratory automation b. Be able to analyze from small volumes c. Have a rapid turnaround time d. Ensure a minimum specimen dead volume

    d. Ensure a minimum specimen dead volume

  • 98

    Which of the following is true regarding POCT? a. Results are generally available more rapidly than with traditional laboratory test. b. POCT is usually less expensive than traditional laboratory measurements c. The device cannot be linked to the hospital information system d. QC samples are not needed.

    a. Results are generally available more rapidly than with traditional laboratory test.

  • 99

    Quality control lockout: a. Prevents quality control from being recorded when outside 2 standard deviations b. Prevents testing when quality control has not been performed c. Prevents operators from changing quality control records d. Prevents the wrong quality control material to be used for a particular test.

    b. Prevents testing when quality control has not been performed

  • 100

    Which of the following is NOT a driving force for more automation? a. Increased use of chemistry panels b. High-volume testing c. fast turnaround time d. Expectation of high-quality, accurate results.

    a. Increased use of chemistry panels

  • 関連する問題集

    other names parasitology

    問題数 702023/11/10

    PARASITOLOGY

    問題数 1112023/11/10

    HTMLBE

    問題数 642023/07/09

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    問題数 612023/11/27

    HISTOPATHOLOGY

    問題数 692023/11/10

    CC-2 SPECTROPHOTOMETRY

    問題数 1002023/11/27

    CC-3 ELECTROPHORESIS

    問題数 412023/11/27

    AUBF LAB SAFETY

    問題数 872023/11/29

    CSF 1

    問題数 1002023/12/07

    CSF 2

    問題数 822023/12/07

    SEMEN 1

    問題数 1002023/12/07

    SEMEN 2

    問題数 72023/12/07

    SYNOVIAL FLUID 1

    問題数 1002023/12/07

    SYNOVIAL FLUID 2

    問題数 62023/12/07

    SEROUS FLUID

    問題数 252023/12/07

    PLEURAL FLUID

    問題数 442023/12/07

    PERICARDIAL FLUID

    問題数 182023/12/07

    PERITONEAL FLUID/ ASCITIC FLUID

    問題数 302023/12/08

    AMNIOTIC FLUID

    問題数 922023/12/08

    FECALYSIS

    問題数 802023/12/08

    OTHER BODY FLUIDS

    問題数 892023/12/08

    MTLBE- SUHO NOTES

    問題数 862023/12/11

    MTLBE..

    問題数 352023/12/11

    CC- CHROMATOGRAPHY

    問題数 192024/04/15

    CC-OSMOMETRY

    問題数 142024/04/15

    CC-ELECTROCHEMISTRY TECHNIQUES

    問題数 432024/04/15

    CC- CARBOHYDRATES

    問題数 492023/12/21

    CC- DIABETES MELLITUS

    問題数 972023/12/22

    MAJOR LIPOPROTEINS

    問題数 572023/12/23

    MINOR LIPOPROTEINS

    問題数 632023/12/23

    PROTEINS

    問題数 372023/12/23

    PLASMA PROTEINS 1

    問題数 912023/12/23

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    問題数 982023/12/23

    MISCELLANEOUS PROTEINS

    問題数 612023/12/23

    Liver Function Test 1

    問題数 1002023/12/23

    Liver Function Test 2

    問題数 962023/12/24

    TUMOR MARKERS

    問題数 332023/12/24

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    問題数 412023/12/24

    GLYCOGEN STORAGE DISEASES

    問題数 172024/02/12

    LIPID STORAGE DISEASES

    問題数 142024/02/12

    PROTEINS

    問題数 712024/02/12

    QUICK FIRE- ELECTRODES

    問題数 72024/02/12

    ELECTROLYTES

    問題数 102024/02/13

    DRUGS

    問題数 272024/02/15

    TOXIC AGENTS:

    問題数 122024/02/15

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    問題数 1002023/12/29

    HEMATOLOGY (HEMATOPOIESIS 2)

    問題数 292023/12/29

    hema diseases

    問題数 252024/01/10

    AML

    問題数 432024/01/16

    GLOBIN SYNTHESIS

    問題数 712024/01/23

    HEMATOLOGY REFERENCE RANGES

    問題数 312024/01/24

    DISORDERS OF PRIMARY HEMOSTASIS

    問題数 342024/01/24

    PLATELET DISORDERS

    問題数 372024/01/24

    CHARACTERISTICS OF CLOTTING FACTORS

    問題数 1002024/01/25

    4. CLASSIFICATION OF MACROPHAGE

    問題数 122024/01/26

    3. NATURAL OR INNATE IMMUNITY

    問題数 392024/01/26

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    問題数 552024/01/26

    6. PHAGOCYTOSIS Chemotaxis

    問題数 372024/01/26

    8. NATURE OF ANTIGEN

    問題数 442024/01/26

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    問題数 502024/01/26

    1. HISTORY

    問題数 692024/01/26

    2. TYPES OF IMMUNITY

    問題数 382024/01/26

    7. PHAGOCYTOSIS Engulfment and Digestion

    問題数 212024/01/26

    8. PHAGOCYTOSIS EXOCYTOSIS

    問題数 152024/01/26

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    問題数 322024/01/26

    11. TRANSPLANTATION IMMUNOLOGY

    問題数 302024/01/26

    2. LYMPHOID ORGANS

    問題数 382024/01/27

    3. CLUSTER OF DIFFERENTIATION

    問題数 482024/01/27

    4. T-CELL DIFFERENTIATION

    問題数 352024/01/27

    5. T CELL IMMUNODEFICIENCIES

    問題数 182024/01/27

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    問題数 442024/01/27

    7. B CELL IMMUNODEFICIENCIES

    問題数 232024/01/27

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    問題数 342024/01/27

    9. COMPARISON OF T AND B CELLS

    問題数 122024/01/27

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    問題数 162024/01/27

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    問題数 152024/01/27

    12. ANTIBODY

    問題数 792024/01/27

    13. TYPES OF ANTIBODIES

    問題数 972024/01/29

    14. MONOCLONAL ANTIBODIES

    問題数 112024/01/29

    1. INTERLEUKINS

    問題数 232024/01/27

    2. INTERFERONS

    問題数 282024/01/28

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    問題数 82024/01/29

    4. COMPLEMENT SYSTEM

    問題数 192024/01/29

    15. COMPLEMENT SYSTEM

    問題数 762024/01/29

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    問題数 212024/01/29

    17. COMPLEMENT AND DISEASE STATES

    問題数 292024/01/29

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    問題数 192024/01/29

    19. CYTOKINES

    問題数 222024/01/29

    20. INTERLEUKINS

    問題数 242024/01/29

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    問題数 212024/01/29

    1. SERO

    問題数 542024/01/30

    2. PRECIPITATION

    問題数 382024/01/30

    3. PASSIVE IMMUNODIFFUSION

    問題数 172024/01/30

    4. OUCHTERLONY

    問題数 152024/01/30

    5. ELECTROPHORETIC TECHNIQUE

    問題数 92024/01/30

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    問題数 112024/01/30

    7. IMMUNOFIXATION ELECTROPHORESIS

    問題数 292024/01/30

    8. COMPARISON OF PRECIPITATION TECHNIQUES

    問題数 222024/01/30

    9. AGGLUTINATION

    問題数 422024/01/30

    12. SKIN TESTS

    問題数 122024/01/31

    13. AUTOIMMUNE DISEASE

    問題数 492024/01/31

    IS

    問題数 112024/01/31

    10. LABELED IMMUNOASSAYS

    問題数 362024/01/31

    11. HYPERSENSITIVITY

    問題数 182024/01/31

    14. SYSTEMIC AUTOIMMUNE DISEASE

    問題数 262024/01/31

    15. BACTERIAL IMMUNOLOGY

    問題数 872024/01/31

    16. VIRAL IMMUNOLOGY

    問題数 722024/01/31

    17. HUMAN IMMUNODEFICIENCY VIRUS (HIV)

    問題数 492024/01/31

    HYPERSENSITIVITY

    問題数 82024/02/01

    RICKETTSIAL DISEASE

    問題数 142024/02/01

    1. HISTORY

    問題数 232024/02/01

    2. GENETICS

    問題数 192024/02/02

    3. ISBT

    問題数 962024/02/02

    11. DEFFERALS

    問題数 762024/01/12

    13. DONOR SCREENING PHYSICAL EXAM

    問題数 92024/01/12

    4. POLYAGGLUTINATION

    問題数 212024/02/04

    5. BLOOD GROUP CHARACTERISTICS

    問題数 72024/02/04

    6. ISBT 002: MNSs

    問題数 232024/02/04

    7. ISBT 003: P

    問題数 282024/02/04

    8. RH BLOOD GROUP (ISBT 004)

    問題数 212024/02/04

    9. OTHER ISBT I

    問題数 1002024/02/04

    10. OTHER ISBT II

    問題数 542024/02/04

    12. SYSTEM #

    問題数 462024/02/04

    DONATION FREQUENCY

    問題数 62024/02/04

    IS

    問題数 732024/02/05

    IMMUNOLOGY

    問題数 1002024/02/07

    IMMUNOLOGY 2

    問題数 862024/02/07

    IMMUNOHEMATOLOGY I

    問題数 1002024/02/07

    IMMUNOHEMATOLOGY 2

    問題数 1002024/02/07

    IMMUNOHEMATOLOGY 3

    問題数 222024/02/07

    MUST KNOW RMT 2024

    問題数 772024/02/09

    HISTORY

    問題数 172024/02/15

    STERILIZATION AND DISINFECTION

    問題数 972024/02/15

    STERILIZATION.

    問題数 262024/02/16

    MICROBIOLOGY SAFETY

    問題数 612024/02/16

    QUALITY MANAGEMENT

    問題数 672024/02/16

    Processes in the Microbiology LaboratoryCOLLECTION AND SPECIMEN HANDLING

    問題数 932024/02/16

    SMEAR AND STAIN PREPARATIONS

    問題数 892024/02/16

    MICROSCOPY

    問題数 382024/02/16

    TRADITIONAL CULTIVATION AND IDENTIFICATION

    問題数 542024/02/16

    MEDIUM

    問題数 1262024/02/16

    PRINCIPLES OF IDENTIFICATION

    問題数 112024/02/16

    ANTIBOTIC SUSCEPTIBILITY I

    問題数 942024/02/16

    ANTIBOTIC SUSCEPTIBILITY II

    問題数 442024/02/16

    BACTERIAL CHARACTERISTICS

    問題数 872024/02/16

    HOST-BACTERIA RELATIONSHIP

    問題数 162024/02/16

    PATHOGENESIS

    問題数 192024/02/16

    BACTERIOLOGY PREVIEW

    問題数 202024/02/16

    AEROBIC COCCI:GRAM POSITIVE

    問題数 92024/02/16

    STAPHYLOCOCCUS AUREUS

    問題数 1002024/02/16

    OTHER STAPHYLOCOCCUS

    問題数 162024/02/18

    STREPTOCOCCUS

    問題数 1002024/02/18

    STREPTOCOCCUS.

    問題数 982024/02/18

    AEROBIC COCCI:GRAM NEGATIVE

    問題数 1002024/02/18

    AEROBIC COCCI:GRAM NEGATIVE.. ANAEROBIC COCCI: GRAM POSITIVE

    問題数 252024/02/18

    NONSPOREFORMER NONBRANCHING CATALASE POSITIVE: Corynebacterium

    問題数 792024/02/19

    NONSPOREFORMER NONBRANCHING CATALASE POSITIVE: LISTERIA

    問題数 432024/02/19

    NONSPOREFORMER NONBRANCHING CATALASE NEGATIVE:

    問題数 392024/02/19

    NONSPOREFORMER BRANCHING BACILLI:

    問題数 672024/02/19

    BACTE

    問題数 572024/02/24

    PARASITOLOGY

    問題数 862024/02/24

    HEMATOLOGY

    問題数 312024/02/24

    CLINICAL CHEMISTRY

    問題数 252024/02/24

    MICRO

    問題数 682024/02/24

    PARA

    問題数 52024/02/24

    ISBB

    問題数 502024/02/24

    COMMON NAME ORGANISM

    問題数 252024/02/25

    ORGANISM VIRULENCE FACTOR(S)

    問題数 312024/02/25

    ORGANISM

    問題数 432024/02/25

    ORGANISM MOTILITY PATTERN

    問題数 112024/02/25

    ORGANISM CHARACTERISTICS (SHAPE/ODOR/COLOR)

    問題数 352024/02/25

    AUBF FINAL COACHING PART 1

    問題数 1002024/02/26

    AUBF FINAL COACHING PART 2

    問題数 102024/02/26

    HISTO

    問題数 682024/02/26

    TUMOR MARKER

    問題数 192024/02/26

    HISTO

    問題数 512024/02/27

    STAINS

    問題数 642024/02/27

    TERMS RELATED TO CYTOPATHOLOGIC CHANGES IN DISEASE

    問題数 412024/02/27

    CM

    問題数 422024/03/06

    LMR 1

    問題数 1002024/02/28

    LMR 2

    問題数 1002024/02/28

    LMR 3

    問題数 1002024/02/28

    BACTERIOLOGY

    問題数 1082024/03/09

    KAPNIEL MICRO PARA

    問題数 1002024/03/10

    KAPNIEL MICRO-PARA

    問題数 952024/03/10

    BACTERIOLOGY..

    問題数 782024/03/10

    BACTERIOLOGY.

    問題数 1002024/03/10

    CLINICAL CHEMISTRY

    問題数 1002024/03/10

    CLINICAL CHEMISTRY.

    問題数 1002024/03/10

    CLINICAL CHEMISTRY/

    問題数 1002024/03/11

    Clinical Chemistry

    問題数 702024/03/11

    LMR 4

    問題数 1002024/03/11

    LMR 5

    問題数 1002024/03/12

    LMR 6

    問題数 1002024/03/12

    LMR 7

    問題数 1002024/03/12

    LMR 8

    問題数 1002024/03/12

    LMR 9

    問題数 1002024/03/12

    LMR 10

    問題数 1002024/03/12

    LMR 11

    問題数 1002024/03/12

    LMR 12

    問題数 1002024/03/12

    LMR 13

    問題数 1002024/03/12

    LMR 14

    問題数 1002024/03/12

    LMR 15

    問題数 992024/03/12

    RECALLS

    問題数 1002024/03/12

    RECALLS.

    問題数 682024/03/12

    CLINICAL CHEMISTRY HARR

    問題数 1002024/03/13

    CLINICAL CHEMISTRY HARR

    問題数 1002024/03/13

    CLINICAL CHEMISTRY HARR

    問題数 1002024/03/13

    CLINICAL CHEMISTRY HARR

    問題数 1002024/03/13

    CLINICAL CHEMISTRY HARR

    問題数 1002024/03/13

    CLINICAL CHEMISTRY HARR

    問題数 692024/03/13

    MICROBIOLOGY BOC

    問題数 1002024/03/14

    MICROBIOLOGY BOC

    問題数 1002024/03/14

    MICROBIOLOGY BOC

    問題数 1002024/03/14

    MICROBIOLOGY BOC

    問題数 1002024/03/14

    1

    問題数 1002024/03/15

    2

    問題数 1002024/03/15

    3

    問題数 402024/03/15

    1

    問題数 1002024/03/15

    2

    問題数 1002024/03/15

    HEMATOLOGY

    問題数 1002024/03/16

    HEMATOLOGY

    問題数 1002024/03/16

    HEMATOLOGY

    問題数 1002024/03/16

    HEMATOLOGY

    問題数 1002024/03/16

    HEMATOLOGY

    問題数 162024/03/16

    1

    問題数 1002024/03/17

    2

    問題数 1002024/03/17

    3

    問題数 822024/03/17

    1

    問題数 1002024/03/18

    2

    問題数 502024/03/18

    1

    問題数 1002024/03/18

    2

    問題数 232024/03/18

    PARASITOLOGY

    問題数 1002024/03/18

    PARASITOLOGY

    問題数 752024/03/18

    CLINICAL CHEMISTRY

    問題数 1002024/03/20

    MICROBIOLOGY

    問題数 1002024/03/20

    CLINICAL MICROSCOPY

    問題数 1002024/03/20

    HEMATOLOGY

    問題数 1002024/03/21

    ISBB

    問題数 1002024/03/21

    MTLBE

    問題数 1002024/03/21

    MUST KNOWS 1

    問題数 1002024/04/04

    MUST KNOW 2

    問題数 1002024/04/04

    MUST KNOW 3

    問題数 522024/04/04

    Introduction

    問題数 522024/04/15

    Basic Approaches to Automation

    問題数 52024/04/15

    Laboratory Apparatus:

    問題数 462024/04/15

    Patient Preparation and Analyte Variation

    問題数 492024/04/15

    Specimen Collection and Handling

    問題数 1002024/04/15

    Specimen Collection and Handling

    問題数 222024/04/15

    Quality in the Laboratory

    問題数 1002024/04/16

    QUALITY IN THE LABORATORY

    問題数 1002024/04/16

    QUALITY IN THE LABORATORY

    問題数 272024/04/16

    Gestational Diabetes Mellitus (GDM)

    問題数 252024/04/16

    CSF Glucose

    問題数 552024/04/16

    Lactate

    問題数 172024/04/16

    Lipids

    問題数 152024/04/16

    TRIGLYCERIDE/TRIACYLGLYCEROL (NEUTRAL FAT)

    問題数 432024/04/16

    Cholesterol

    問題数 542024/04/16

    Lipoproteins

    問題数 362024/04/16

    CC

    問題数 252024/04/19

    CC PRE-TEST

    問題数 342024/04/20

    MICROBIOLOGY AND PARASITOLOGY PRE-TEST

    問題数 352024/04/20

    CLINICAL MICROSCOPY PRE-TEST

    問題数 332024/04/20

    HEMATOLOGY PRE-TEST

    問題数 322024/04/20

    IMMUNOLOGY-SEROLOGY AND BLOOD BANKING PRE-TEST

    問題数 352024/04/21

    HTMLE PRE-TEST

    問題数 282024/04/21

    POPCORN

    問題数 1002024/04/23

    MICROBIOLOG/PARASITOLOGY

    問題数 82024/04/23

    POPCORN

    問題数 1002024/05/04

    MICRO

    問題数 72024/05/29

    BALUT TUWING GABI 🐣

    問題数 632024/06/07

    POPCORN

    問題数 1002024/07/01

    POPCORN

    問題数 1002024/07/01

    POPCORN

    問題数 1002024/07/02

    POPCORN

    問題数 1002024/07/02

    POPCORN

    問題数 1002024/07/02

    POPCORN

    問題数 1002024/07/02

    CC

    問題数 272024/07/03

    AUBF- STRASINGER

    問題数 1002024/07/03

    AUBF STRASINGER

    問題数 1002024/07/03

    AUBF- STRASINGER

    問題数 1002024/07/03

    AUBF- STRASINGER

    問題数 1002024/07/03

    AUBF- STRASINGER

    問題数 932024/07/03

    MICROBIOLOGY PROGRESS EXAM

    問題数 1002024/07/08

    MICROBIOLOGY PROGRESS EXAM

    問題数 162024/07/08

    PARASITOLOGY PROGRESS EXAM

    問題数 1002024/07/09

    HEMATOLOGY PROGRESS EXAM

    問題数 1002024/07/10

    HEMATOLOGY PROGRESS EXAM

    問題数 252024/07/10

    CLINICAL MICROSCOPY PROGRESS EXAM

    問題数 1002024/07/10

    CLINICAL MICROSCOPY PROGRESS EXAM

    問題数 252024/07/10

    BLOOD BANKING PROGRESS EXAM

    問題数 1002024/07/11

    BLOOD BANKING PROGRESS EXAM

    問題数 62024/07/11

    IMMUNOLOGY & SEROLOGY PROGRESS EXAM

    問題数 1002024/07/11

    IMMUNOLOGY & SEROLOGY PROGRESS EXAM

    問題数 452024/07/11

    POPCORN

    問題数 1002024/07/11

    HISTOPATHOLOGY & MT LAWS PROGRESS EXAM

    問題数 1002024/07/12

    HISTOPATHOLOGY & MT LAWS PROGRESS EXAM

    問題数 252024/07/12

    POPCORN

    問題数 1002024/07/13

    SUMMATIVE EXAM PART 1

    問題数 1002024/07/23

    SUMMATIVE EXAM PART 1

    問題数 602024/07/23

    ELECTROLYTES

    問題数 82024/07/23

    ELECTROLYTES REFERENCE RANGE: PLASMA, SERUM

    問題数 132024/07/23

    SUMMATIVE PART 2

    問題数 1002024/07/23

    SUMMATIVE PART 2

    問題数 502024/07/24

    CLINICAL CHEMISTRY PROGRESS EXAM PART 2

    問題数 1002024/07/24

    CLINICAL CHEMISTRY PROGRESS EXAM PART 2

    問題数 262024/07/24

    ELECTROPHORETIC PATTERNS

    問題数 92024/07/24

    SUMMATIVE EXAM PART 3

    問題数 1002024/07/24

    SUMMATIVE EXAM PART 3

    問題数 902024/07/24

    MICROBIOLOGY & PARASITOLOGY PROGRESS EXAM PART 2

    問題数 1002024/07/25

    MICROBIOLOGY & PARASITOLOGY PROGRESS EXAM PART 2

    問題数 322024/07/25

    CLINICAL CHEMISTRY

    問題数 1002024/07/26

    CLINICAL CHEMISTRY

    問題数 122024/07/26

    HTMLE

    問題数 902024/07/26

    MICROBIOLOGY AND PARASITOLOGY

    問題数 1002024/07/26

    CLINICAL MICROSCOPY

    問題数 1002024/07/26

    HEMATOLOGY

    問題数 1002024/07/26

    CLINICAL MICROSCOPY PROGRESS EXAM PART 2

    問題数 1002024/07/26

    CLINICAL MICROSCOPY PROGRESS EXAM PART 2

    問題数 352024/07/26

    HEMATOLOGY

    問題数 112024/07/27

    IMMUNOLOGY AND SEROLOGY

    問題数 602024/07/27

    BLOOD BANKING

    問題数 402024/07/27

    HEMATOLOGY PROGRESS EXAM PART 2

    問題数 1002024/07/27

    HEMATOLOGY PROGRESS EXAM PART 2

    問題数 352024/07/27

    CLINICAL CHEMISTRY MARCH 2024

    問題数 512024/07/28

    MICROBIOLOGY AND PARASITOLOGY

    問題数 632024/07/28

    CLINICAL MICROSCOPY

    問題数 502024/07/28

    HEMATOLOGY

    問題数 382024/07/28

    BLOOD BANKING AND SEROLOGY

    問題数 282024/07/28

    HTMLE

    問題数 442024/07/28

    ISBB PROGRESS EXAM PART 2

    問題数 1002024/07/28

    SUMMATIVE EXAM #4

    問題数 1002024/07/29

    SUMMATIVE EXAM #4

    問題数 1002024/07/29

    CLINICAL CHEMISTRY

    問題数 1002024/07/30

    CLINICAL CHEMISTRY

    問題数 1002024/07/30

    CLINICAL CHEMISTRY

    問題数 322024/07/30

    HISTOPATHOLOGY & MT LAWS PROGRESS EXAM PART 2

    問題数 1002024/07/30

    HISTOPATHOLOGY & MT LAWS PROGRESS EXAM PART 2

    問題数 522024/07/30

    SUMMATIVE EXAM #4

    問題数 302024/07/31

    POPCORN

    問題数 152024/07/31

    ABO Blood Group System

    問題数 152024/07/31

    Rh Blood Group System Quiz

    問題数 152024/07/31

    Non-ABO/Rh Blood Groups Quiz

    問題数 92024/07/31

    Blood Groups: Name That Null!

    問題数 102024/07/31

    MICROBIOLOGY

    問題数 802024/08/01

    Blood Groups Practical Theory Quiz

    問題数 102024/08/01

    Blood Administration Quiz

    問題数 112024/08/01

    ISBB

    問題数 1002024/08/01

    ISBB

    問題数 522024/08/01

    BLOOD BANKING

    問題数 922024/08/01

    RODAKS HEMATOLOGY

    問題数 1002024/08/01

    RODAKS HEMATOLOGY

    問題数 1002024/08/01

    SUMMATIVE EXAM 5

    問題数 1002024/08/01

    SUMMATIVE EXAM 5

    問題数 1002024/08/02

    SUMMATIVE EXAM 5

    問題数 232024/08/02

    SUMMATIVE EXAM #6

    問題数 1002024/08/02

    SUMMATIVE EXAM #6

    問題数 892024/08/02

    SUMMATIVE EXAM #7

    問題数 1002024/08/03

    Clinical Chemistry

    問題数 512024/08/04

    SUMMATIVE EXAM #8

    問題数 1002024/08/05

    SUMMATIVE EXAM #8

    問題数 312024/08/05